Search results
Results From The WOW.Com Content Network
Dacarbazine, also known as imidazole carboxamide and sold under the brand name DTIC-Dome, is a chemotherapy medication used in the treatment of melanoma and Hodgkin's lymphoma. [3] For Hodgkin's lymphoma it is often used together with vinblastine, bleomycin, and doxorubicin. [3] It is given by injection into a vein. [3]
In September 2014, a new cancer immunotherapy for melanoma patients called Keytruda became the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States. Jeffrey Weber, director of the Donald A. Adam Comprehensive Melanoma Research Center of Excellence at Moffitt, was one of the lead investigators of the clinical trial ...
On February 1, 2012, Health Canada approved ipilimumab for "treatment of unresectable or metastatic melanoma in patients who have failed or do not tolerate other systemic therapy for advanced disease." [24] Ipilimumab was approved in the European Union (EU), for second line treatment of metastatic melanoma in November 2012. [25] [26]
Micrograph showing a PD-L1 positive non-small cell lung carcinoma. PD-L1 immunostain. As of 2019, pembrolizumab is used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain situations, as a first-line treatment for metastatic bladder cancer in patients who cannot receive cisplatin-based chemotherapy and have high levels ...
Combinatorial ablation and immunotherapy enhances the immunostimulating response and has synergistic effects for metastatic cancer treatment. [ 174 ] Combining checkpoint immunotherapies with pharmaceutical agents has the potential to improve response, and as of 2018 were a target of clinical investigation. [ 175 ]
An investigational mRNA vaccine used along with immunotherapy continues to show benefit for people with high-risk forms of the skin cancer melanoma, the drugmakers said Thursday.
Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [ 16 ] Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [ 17 ]
The current approach to treating melanoma with immunotherapy includes three broad categories of treatments including cytokines, immune check point inhibitors, and adoptive cell transfer. [136] These treatment options are most often used in people with metastatic melanoma and significantly improves overall survival. [124]